Home › Endometrial Cancer › Tennessee
Endometrial Cancer clinical trials in Tennessee
40 studies for Endometrial Cancer are looking for participants at sites in Tennessee.
Cities in Tennessee
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06270706Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Regional Cancer Center at Johnson City Medical Center, Johnson City
- Ballad Health Cancer Care - Kingsport, Kingsport
- and 3 more
RecruitingPhase 2
All ages · All sexes · Updated Nov 12, 2026 · NCT05564377A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- SCRI Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Erlanger Medical Center ( Site 5009), Chattanooga
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT06952504A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07503808A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Vanderbilt-Ingram Cancer Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06515613Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Vanderbilt-Ingram Cancer Center Cool Springs, Franklin
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 6, 2026 · NCT07198074A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Nov 5, 2026 · NCT06586957Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06760819A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- SCRI Oncology Partners, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06695845Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 30, 2026 · NCT07578649A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06774963A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Sarah Cannon Nashville, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07109726A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06330064A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478A Phase 1 Study of the Safety and Tolerability of CTX-10726
- SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07419841A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- SCRI Oncology Partners - Nashville, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07383506A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT04657068Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06239194Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Oct 9, 2026 · NCT06276491FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT05919264A Study of PHST001 in Advanced Solid Tumors
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06840886The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750DESTINY-PANTUMOUR04
- Research Site, Nashville
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Nashville
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07213609Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT07755436Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Knoxville
- Research Site, Nashville
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- The West Clinic, PLLC dba West Cancer Center, Germantown
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Tennessee Oncology, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT05941507A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Feb 13, 2025 · NCT05669430From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.